Navigation Links
AutoImmune Inc. Reports 2008 Third Quarter Financial Results
Date:11/7/2008

PASADENA, Calif., Nov. 7 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net loss of $23,000, or break even per share basic and diluted, for the three months ended September 30, 2008, compared with a net loss of $8,000, or break even per share basic and diluted, for the three months ended September 30, 2007. For the nine months ended September 30, 2008, the net loss was $216,000, or $0.01 per share basic and diluted, compared with net loss of $62,000, or break even per share basic and diluted for the same period in 2007. As of September 30, 2008, the Company reported $8.6 million in cash and marketable securities as compared to $8.8 million in cash and marketable securities as of December 31, 2007.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "Product sales at Colloral LLC during the third quarter were unchanged from the same period prior year." AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46 "Consolidation of Variable Interest Entities."

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug, MBP8298, if it reaches the market. In December 2007, BioMS sublicensed its rights in this product to Eli Lilly and Company. During the third quarter just completed, BioMS announced the product was granted fast track designation by the FDA and that it had received a milestone payment from Eli Lilly for successfully passing an interim analysis for safety and futility in its pivotal phase II/III trial of MBP8208 for treatment of secondary progressive multiple sclerosis. We expect the final trial data will be available during the second half of 2009.

AutoImmune is a biopharmaceutical company involved in the development of
'/>"/>

SOURCE AutoImmune Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related biology technology :

1. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
2. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
3. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
4. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
5. Dendreon Reports Third Quarter 2008 Financial Results
6. Osteotech Reports 2008 Third Quarter Financial Results
7. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
8. Oncothyreon reports third quarter 2008 financial results
9. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
10. NeurogesX Reports Third Quarter 2008 Results
11. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...e-FirstCall/ -- IES (Nasdaq: IESC ), a leading na...ystems and services for the commercial, industrial... commercial business group has been awarded a cont...rical systems for the Level 4 bio-safety lab (BSL-...esearch Institute of Infectious Diseases (USAMRIID...
(Date:11/24/2009)...land, November 24 deCODE...at it has received notice from,the Nasdaq Stock Ma...ll be,suspended as of November 30, 2009 and a Form...ange Commission, which will remove deCODE,s common...files an appeal to the Nasdaq,Listing Qualificatio...
(Date:11/24/2009)... NeurogesX, Inc. (Nasdaq:...eveloping and commercializing novel pain managemen... President and Chief Executive Officer, is schedul...lth Care Conference, to be held December 1-2, 2009...k. ,, Mr. DiTonno and Stephen Ghiglieri, Chief...
(Date:11/24/2009)...O, Nov. 24 /PRNewswire-FirstCall/ - Hamilton Thorn..., a leading provider of advanced laser systems and...ity clinic markets, today reported operational and...tember 30, 2009. , , Q3 2009 Highlights, -...illion in Q3 2008, - Gross profit margin was ...
Breaking Biology Technology:Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10
...attendees from 47 countries convene in Seattle for...ce, SEATTLE, Aug. 20 More than 900 global resear...k for the AIDS Vaccine 2007,Conference at the Sher...ine,2000 Conference in Paris, this event has emerg...ific information relating to the difficult task of...
...ug. 14 Transgenomic, Inc. (the,"Company") (OTC Bu...lts for,the quarter ended June 30, 2007. The Compa... that follow. Second Quarter 2007 The Company re...hare,for the second quarter of 2007 as compared to... the second quarter of 2006. The 2007 net profit w...
...ug. 14 Response Genetics, Inc.,(Nasdaq: RGDX ), ...arter,ended June 30, 2007. "The second quarter of...nning with our successful initial public offering ...EO of Response Genetics. "We are very,pleased by t...ced. During,the quarter these developments include...
Other Biology Technology:Global Experts Explore Entire Spectrum of Aids Vaccine Development 2Transgenomic, Inc. Reports Second Quarter 2007 Results 2Transgenomic, Inc. Reports Second Quarter 2007 Results 3Transgenomic, Inc. Reports Second Quarter 2007 Results 4Transgenomic, Inc. Reports Second Quarter 2007 Results 5Transgenomic, Inc. Reports Second Quarter 2007 Results 6Transgenomic, Inc. Reports Second Quarter 2007 Results 7Transgenomic, Inc. Reports Second Quarter 2007 Results 8Response Genetics Reports Second Quarter 2007 Financial Results 2Response Genetics Reports Second Quarter 2007 Financial Results 3Response Genetics Reports Second Quarter 2007 Financial Results 4Response Genetics Reports Second Quarter 2007 Financial Results 5Response Genetics Reports Second Quarter 2007 Financial Results 6Response Genetics Reports Second Quarter 2007 Financial Results 7Response Genetics Reports Second Quarter 2007 Financial Results 8
(Date:11/24/2009)...NEW YORK (November 24, 2009) -- The Wildlife Conse...ealing that the last remaining population of Siber...o the rising tide of poaching and habitat loss. ,... Russian officials of what needs to be done to pro...cat. , The report was released by t...
(Date:11/24/2009)...s fish food is a matter of debate. A high-profile ...st 50 percent of their carbon from trees and leave...estrial and aquatic ecosystems. , But new resear... not likely to be true. Algae provide a much riche...to research published this week in the Proceeding...
(Date:11/24/2009)... available in Spanish . , The presence of i...inflammatory substances in the blood, hinders the ... research project of the University of Navarra con... the School of Pharmacy. , The project, entitled...n to the control of body weight and inflammation,"...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3It can be predicted the reaction obese patients will have to a diet 2VBI awarded 2427 million from NIH to support infectious disease research 10266 1VBI awarded 2427 million from NIH to support infectious disease research 10266 2VBI awarded 2427 million from NIH to support infectious disease research 10266 3VBI awarded 2427 million from NIH to support infectious disease research 10266 4Expert Panel of Pediatric Liver Specialists Publishes Recommendations for Monitoring and Referral of Children With Chronic Hepatitis B Infections 58887 1Expert Panel of Pediatric Liver Specialists Publishes Recommendations for Monitoring and Referral of Children With Chronic Hepatitis B Infections 58887 2Expert Panel of Pediatric Liver Specialists Publishes Recommendations for Monitoring and Referral of Children With Chronic Hepatitis B Infections 58887 3 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 1 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 2 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 3 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 4 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 5 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 6
...er development may provide protection against high...ording to researchers at Purdue University and the...scovered the new preventative drug and have tested...nes, the new vaccine could be produced quickly and...emic of dangerous disease-causing avian influenza ...
...or truck trailers by mounting sideskirts can lead ...o as much as 15%. Earlier promising predictions, b...by TU Delft, have been confirmed during road tests...rivate platform PART (Platform for Aerodynamic Roa...n immediately be put into production. , It is exp...
... , , Every two minutes in Germany, one person su... not survive the sudden lack of blood in the brain...Since the brain is a high-performance organ with a...gen is interrupted, it reacts with paralyses, impa...ng of the underlying processes in the brain, resea...
Other Biology News:New vaccine may give long-term defense against deadly bird flu and its variant forms 2New vaccine may give long-term defense against deadly bird flu and its variant forms 3New vaccine may give long-term defense against deadly bird flu and its variant forms 4Aerodynamic trailer cuts fuel and emissions by up to 15 percent 2Tracking stroke 2
L-Selenomethionine from Calbiochem
PAP PEN from Invitrogen
EL4 Cell Slide from ProSci, Inc
Jurkat Cell Slide from ProSci, Inc
Biology Products: